Physician profile
Chad Lawrence
NPI 1740617067
$2,424.52
in general payments reported to CMS, 2019-2025
25 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $107 · 2021: $1,322 · 2022: $201 · 2023: $152 · 2024: $173 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Orthopedic Systems | $1,200.00 | 2021 | |
| Abbvie INC. | $235.38 | 2021-2025 | |
| Pacira Therapeutics, INC. | $129.67 | 2019-2021 | |
| Treace Medical Concepts, INC. | $119.41 | 2019 | |
| Medtronic, INC. | $91.10 | 2024-2025 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $84.28 | 2019-2022 | |
| Djo, LLC | $78.73 | 2025 | Cmf |
| Convatec INC. | $73.08 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $68.33 | 2022-2025 | Nuzyra |
| Bioventus LLC | $56.18 | 2019-2022 | |
| Linvatec Corporation | $40.30 | 2023-2024 | Biobrace 23mm, Allograft Tissue |
| Advanced Oxygen Therapy INC. | $33.99 | 2024-2025 | Topical Oxygen Chamber For Extremities |
| Inari Medical, INC. | $24.39 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kerecis Limited | $23.32 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Sanofi-Aventis U.S. LLC | $21.02 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $20.53 | 2023 | Zilretta, Iovera, Exparel |
| Fidia Pharma USA INC. | $20.18 | 2025 | Hymovis |
| Endo USA, INC. | $15.93 | 2025 | Xiaflex |
| Amgen INC. | $15.19 | 2025 | Krystexxa |
| Biocomposites INC | $14.35 | 2023 | Stimulan |
| Medartis INC. | $13.44 | 2020 | |
| Smith+Nephew, INC. | $13.03 | 2020 | |
| Triad Life Sciences INC. | $11.96 | 2022 | |
| Baudax Bio INC. | $11.40 | 2021 | |
| Medela LLC | $9.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.